Multi-Infarct Dementia Market: Global Industry Analysis and Forecast (2021-2027): by Cause, Pharmacological Treatment and Region

Multi-Infarct Dementia Market is anticipated to reach US$ 438.20 Mn. by 2027 from US$ 316 Mn. in 2020 at a CAGR of 5.6 % during a forecast period. A succession of minor strokes causes multi-infract dementia. A stroke, also known as an infarct, is a disruption or stoppage of blood flow to any area of the brain. And the term "multi-infarct" refers to a large number of strokes and regions of damage. Because brain cells can die from a lack of oxygen if blood flow is interrupted for more than a few seconds, and this element can result in irreversible damage. Multi-Infarct Dementia Market To know about the Research Methodology:- Request Free Sample Report In the report, 2020 is considered a base year however 2020’s numbers are on the real output of the companies in the market. Special attention is given to 2020 and the effect of lockdown on the demand and supply, and also the impact of lockdown for the next two years on the market. Some companies have done well in lockdown also and specific strategic analysis of those companies is done in the report.

Multi-Infarct Dementia Market Dynamics:

Vascular dementia is another term for multi-infract dementia. According to the National Institute of Health, multi-infract dementia is the second most common form of dementia. People over the age of 65 are disproportionately afflicted by multi-infract dementia. As a result, an increase in the senior population is likely to support the growth of the multi-infract dementia market. According to the poll, 1-4 people out of every 100 over the age of 65 are at risk of developing vascular dementia. For the treatment of multi-infract dementia, a variety of technologies and diagnostic procedures are employed. Inhibitors have demonstrated preventative effects in vascular dementia, which is another reason driving market growth throughout the forecast period. However, there are no specific therapies supplied by physicians, although some medications, such as dopamine and calcium channel blockers, have demonstrated preventative benefits in treatment choices. Furthermore, the lack of treatment options for vascular dementia diagnosis is expected to drive market growth. In addition, quick development and clinical investigations on the pharmacological activity of pharmaceuticals to provide precise treatment options are expected to drive market growth throughout the forecast period. Furthermore, enhanced medical condition detecting technologies are expected to boost the market for computerized tomography (CT) and magnetic resonance imaging (MRI) (MRI). Furthermore, those with COVID-19 are more probable to create vascular dementia, especially African Americans. Dementia may result in high-risk variables, however, it may not always result in mortality. As the incidence of the COVID-19 pandemic is astonishing in the world and has become a public health hazard, this factor is expected to expedite research investigations on therapy and diagnostic solutions. As a result, this pandemic is expected to promote the growth of vascular dementia during the next few years.

Multi-Infarct Dementia Market Segmentation Analysis

The Cause segment of the Global Multi-Infarct Dementia Market is dominated by the Brain Tumor segment: Brain tumors are the major cause of multi-infract dementia and accounted for the largest market share over the forecast period. A brain tumor can affect or induce cognitive function, as well as headaches, convulsions, and vomiting. Dementia is frequently the first sign of slow-growing cancer. Furthermore, the National Foundation for Cancer Research (NFFCR) reports that around 80,000 brain tumors are diagnosed in the United States each year. And 32% of them are carcinogenic or cancerous. As a result, the brain tumor section can cause brain cell obstruction, which can lead to stroke. When blood flow to the brain is interrupted or reduced, a stroke occurs. Furthermore, a blockage in blood vessels or cells might result in a severe case of Multi-infract dementia. This can potentially result in brain bleeding or a fatal hemorrhagic stroke. Also, around 20% of those over the age of 65. Furthermore, 2-5 percent of people, or 1 in 1000, suffer from deep vein thrombosis blood clots each year. This factor is also expected to enhance the market growth. Deep vein thrombosis, on the other hand, is an uncommon kind of sickness that can have serious consequences. The Memantine segment is expected to contribute to the growth of the Global Multi-Infarct Dementia Market: In 2020, the memantine drug had a market share of about 12.4 percent in the pharmaceutical treatment area. The drug memantine is the only one on the market that has proven results in the market for multi-infract dementia. N-Methyl-D-aspartate receptors (NMDAR) are linked to memory activation, hence overactivation might result in neuron death. Memantine is an extrasynaptic NMDAR antagonist that is now being utilized to treat Alzheimer's disease. Furthermore, memantine reduces neuronal cell death caused by excitotoxicity by reducing the excess activation of extrasynaptic NMDAR disease activity. There have been no clinical trials on memantine as a therapy for vascular dementia, however, it has shown a minor impact. As a result, memantine research investigations are likely to boost the market's growth in the future.

Multi-Infarct Dementia Market Regional Insight

Due to the existence of a senior population in the area, North America dominated the Multi-Infarct Dementia Market with a 42.7 percent market share in 2020. The region's growth may be ascribed to increased exposure to technology as well as advancements in the research and development industry, which includes the latest models of MRI machines and other body scanners. Furthermore, mergers and acquisitions are propelling the Multi-Infarct Dementia Market forward. For example, Janssen Pharmaceuticals, Inc. purchased XBiotech for USD 750 million in 2019. The company went on to buy three other businesses in three different industries, as well as two additional businesses. These mergers and acquisitions are expected to improve the region's research and drug development efforts. During the forecast period, Asia Pacific is acquiring a considerable market share, with the highest CAGR of 6.3 percent. Furthermore, biotechnology and pharmaceutical businesses are propelling the market for therapeutics assays and drug research. Furthermore, the region's growth is being fueled by healthcare initiatives that, with the assistance of commercial or government research institutions, are raising consumer knowledge about illnesses and good lifestyle habits. Furthermore, rising public awareness is expected to boost the market growth. Because of its growing older population, Japan accounts for about half of all dementia cases in the Asia Pacific. Over the forecast period, developed countries such as Japan, Canada, France, Germany, and the United States are expected to see positive growth.

Report Objectives:

• Landscape analysis of the Multi-Infarct Dementia Market • competitive benchmarking • Past and current status of the industry with the forecasted market size and trends • Evaluation of potential key players that include market leaders, followers, and new entrants • Technology trends • Potential impact of micro-economic factors of the market • External and Internal factors affecting market have been analysed The report also helps in understanding the Multi-Infarct Dementia Market dynamics, structure by analysing the market segments and project the Multi-Infarct Dementia Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Multi-Infarct Dementia Market make the report investor’s guide.

Multi-Infarct Dementia Market Scope: Inquire before buying

Multi-Infarct Dementia Market
Report Coverage Details
Base Year: 2020 Forecast Period: 2021-2027
Historical Data: 2016 to 2020 Market Size in 2020: US $ 316 Mn.
Forecast Period 2021 to 2027 CAGR: 5.6  % Market Size in 2027: US $ 438.20 Mn.
Segments Covered: by Cause • Anemia • Brain Tumor • Chronic Infection • Depression • Thyroid Disease • Vitamin Deficiency • Drug Intoxication • Others
by Pharmacological Treatment • Cheis • Donepezil • Galantamine • Rivastigmine • Memantine • Nimodipine • Hydergine, • CDP-Choline • Others

Multi-Infarct Dementia Market, by Region

• North America • Asia pacific • Europe • Middle East and Africa • South America

Multi-Infarct Dementia Market Key Players

• Accelerys, Inc. • Affymetrix • Agilent Technologies • Celera Corporation • Clarius Mobile Health Corp. • DNAnexus • GE Healthcare • IBS Cybernics Centre • Siemens Healthiners • Forest Laboratories, Inc. • Janssen Pharmaceuticals, Inc. • Novartis Pharmaceutical Corporation • Pfizer, Inc

Frequently Asked Questions

1. What is the projected market size & growth rate of Multi-Infarct Dementia Market? Ans- Multi-Infarct Dementia Market was valued at USD 316 million in 2020 and is projected to reach USD 438.20 million by 2027, growing at a CAGR of 5.6 % during the forecast period. 2. What are the key driving factors for the growth of Multi-Infarct Dementia Market? Ans- As a result, an increase in the senior population is likely to support the growth of the multi-infract dementia market. 3. Which Region accounted for the largest Multi-Infarct Dementia Market share? Ans- North America dominated the Multi-Infarct Dementia Market with a 42.7 percent market share in 2020. 4. What makes North America a Lucrative Market for Multi-Infarct Dementia Market? Ans- The region's growth may be ascribed to increased exposure to technology as well as advancements in the research and development industry 5. What are the top players operating in Multi-Infarct Dementia Market? Ans- Accelerys, Inc., Affymetrix, Agilent Technologies, Celera Corporation, Clarius Mobile Health Corp., DNAnexus, and GE Healthcare.
1. Global Multi-Infarct Dementia Market: Research Methodology 2. Global Multi-Infarct Dementia Market : Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Multi-Infarct Dementia Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Multi-Infarct Dementia Market : Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 3.12 COVID-19 Impact 4. Global Multi-Infarct Dementia Market Segmentation 4.1 Global Multi-Infarct Dementia Market, By Cause (2020-2027) • Anemia • Brain Tumor • Chronic Infection • Depression • Thyroid Disease • Vitamin Deficiency • Drug Intoxication • Others 4.2 Global Multi-Infarct Dementia Market, By Pharmacological Treatment (2020-2027) • Cheis • Donepezil • Galantamine • Rivastigmine • Memantine • Nimodipine • Hydergine, • CDP-Choline • Others 5. North America Multi-Infarct Dementia Market (2020-2027) 5.1 North American Multi-Infarct Dementia Market, By Cause (2020-2027) • Anemia • Brain Tumor • Chronic Infection • Depression • Thyroid Disease • Vitamin Deficiency • Drug Intoxication • Others 5.2 North America Multi-Infarct Dementia Market, By Pharmacological Treatment (2020-2027) • Cheis • Donepezil • Galantamine • Rivastigmine • Memantine • Nimodipine • Hydergine, • CDP-Choline • Others 5.3 North America Multi-Infarct Dementia Market, by Country (2020-2027) • United States • Canada • Mexico 6. Asia Pacific Multi-Infarct Dementia Market (2020-2027) 6.1. Asia Pacific Multi-Infarct Dementia Market, By Cause (2020-2027) 6.2. Asia Pacific Multi-Infarct Dementia Market, By Pharmacological Treatment (2020-2027) 6.2. Asia Pacific Multi-Infarct Dementia Market, by Country (2020-2027) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 7. Middle East and Africa Multi-Infarct Dementia Market (2020-2027) 7.1. Middle East and Africa Multi-Infarct Dementia Market, By Cause (2020-2027) 7.2. Middle East and Africa Multi-Infarct Dementia Market, By Pharmacological Treatment (2020-2027) 7.3. Middle East and Africa Multi-Infarct Dementia Market, by Country (2020-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 8. Latin America Multi-Infarct Dementia Market (2020-2027) 8.1. Latin America Multi-Infarct Dementia Market, By Cause (2020-2027) 8.2. Latin America Multi-Infarct Dementia Market, By Pharmacological Treatment (2020-2027) 8.3 Latin America Multi-Infarct Dementia Market, by Country (2020-2027) • Brazil • Argentina • Rest Of Latin America 9. European Multi-Infarct Dementia Market (2020-2027) 9.1. European Multi-Infarct Dementia Market, By Cause (2020-2027) 9.2. European Multi-Infarct Dementia Market, By Pharmacological Treatment (2020-2027) 9.3 European Multi-Infarct Dementia Market, by Country (2020-2027) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 10. Company Profile: Key players 10.1. Accelerys, Inc. 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2. Accelerys, Inc. 10.3. Affymetrix 10.4. Agilent Technologies 10.5. Celera Corporation 10.6. Clarius Mobile Health Corp. 10.7. DNAnexus 10.8. GE Healthcare 10.9. IBS Cybernics Centre 10.10. Siemens Healthiners 10.11. Forest Laboratories, Inc. 10.12. Janssen Pharmaceuticals, Inc. 10.13. Novartis Pharmaceutical Corporation 10.14. Pfizer, Inc

About This Report

Report ID 116292
Category Healthcare
Published Date Aug 2021
Updated Date Dec 2021
Contact Us